ExcelMab Inc. announced today that the company's self-developed HER2×CD3 bispecific antibody drug EX101 injection has completed dosing for the first patient in the phase I clinical trial at Hunan Cancer Hospital.

The first subject in the phase I clinical trial was administered at Hunan Cancer Hospital and is in good condition.

The trial, led by Professor Wang Shusen of Sun Yat-sen University Cancer Center, aims to evaluate the safety, tolerability and pharmacokinetic characteristics of EX101 injection in patients with HER2-positive advanced solid tumors and to explore its anti-tumor activity.

About EX101   

    EX101 injection is a bispecific antibody drug targeting HER2 and CD3 , developed based on ExMab®, ExcelMab's bispecific antibody platform, for the treatment of HER2-positive advanced solid tumors. Compared with the international molecules in development for the same targets, EX101 injection has remarkable efficacy and greatly improved safety, and its therapeutic window is 20 times that of similar products in development, which will provide patients with a new safer and more effective treatment option in the future.